Impact of COVID-19 on Prenatal Testing and Newborn Screening in Healthcare Industry

OVERVIEW AFTERMATH OF COVID-19 AND GOVERNMENT ROLE
A recent SARS-CoV-2, virus has caused a general pandemic of respiratory disease, called COVID-19. The infection initially showed up in Wuhan, a city in China, in December 2019. The patients experiencing COVID-19 are cautiously dealt with all the safety measures since this sickness spreads quicker through actual contact.
There are now numerous vaccines in use. The first mass vaccination program commenced in early December 2020 and as of 15 February 2021, 175.3 million vaccine doses have been administered.
World Health Organization (WHO) issued an Emergency Use Listing (EULs) for the Pfizer COVID-19 vaccine (BNT162b2) on 31 December 2020, issued another two EULs for two versions of the AstraZeneca/Oxford COVID-19 vaccine, manufactured by the Serum Institute of India and SKBio on 15 February 2021. On 12 March 2021, WHO issued a EUL for the COVID-19 vaccine Ad26.COV2.S, developed by Janssen (Johnson & Johnson)
As per the WHO report, globally, as of 2 June 2021, there have been 170,812,850 confirmed cases of COVID-19, including 3,557,586 deaths, reported to WHO. As of 2 June 2021, a total of 1,581,509,628 vaccine doses have been administered.
As per the WHO report, in the United States of America, from 3 January 2020 to 4:26pm CEST, 2 June 2021, there have been 32,942,677 confirmed cases of COVID-19 with 588,866 deaths, reported to WHO. As of 27 May 2021, a total of 294,270,594 vaccine doses have been administered.
Even though immunization is found for COVID-19, safeguards incorporate incessant hand-wash, wearing a face veil, and keeping up social separating.
The goal of new born screening is the pre-symptomatic detection of infants with congenital conditions so that treatment may be commenced at the earliest to prevent, or improve, the long-term
In light of the fiery impacts of the infection, there are hypothetical dangers that the viral contamination could delay the prenatal testing and newborn screening as there have been limited visits to the hospitals and testing centers due to the lockdown imposed by the government in different countries.
Newborn screening is a public health service done in every U.S. state. A cluster of health disorders that remains inconspicuous at birth is tested for every newborn. Every newborn is tested for a group of health disorders that aren't otherwise found at birth.
With a simple blood test, doctors can check for rare genetic, hormone-related, and metabolic conditions that can cause serious health problems. Newborn screening lets doctors diagnose babies rapidly and commence treatment as soon as possible.

STRATEGIC DECISIONS OF GOVERNMENT AND MANUFACTURERS
The key players engaged in global wound healing manufacturing are making improvements to keep the speed during COVID-19. They are taking every single choice cautiously to expand on a consistent schedule for the market. The manufacturers are likewise giving a great deal of consideration in improving inventive items that can be utilized for the attractive impacts. Organizations working in the minimally invasive gastrointestinal surgical systems market embrace a few systems, including joint effort, arrangements, association, and market development, to improve their business. These essential choices by the organizations must give huge occasions to the market players working in the minimally invasive gastrointestinal surgical systems market.
For instance,
• December 2017, Eone-Diagnomics Genome Center (EDGC), a Korean genetic analysis company, announced its decision to apply machine learning-based artificial intelligence (AI) technology to its non-invasive prenatal test (NIPT) NICE 0. In 2019, AI specialist FDNA and PerkinElmer Genomics partnered to launch Face2Gene Labs for newborn testing. This decision enabled the company to flourish further in the market and helps in revenue generation

IMPACT ON DEMAND
Since the pandemic, due to the lockdown situation, the economic growth of a country is declining day by day. And the manufacturing units for various items shut down due to the non-availability of manpower.
There will be opportunities in the coming time for manufacturers of digital health technologies to position themselves for the COVID-19 recovery. When COVID-19 responses ease, there will be an excess of elective surgeries procedures in emergency clinics. The pre-appointment programs can help smooth out the planning, arrangement, and conveyance of the medical professionals and the doctors.
For instance,
• CVS is a type of diagnostic test performed between 10.5 to 13.5 weeks of pregnancy. The procedure involves obtaining a small tissue sample from the placenta by inserting a thin needle through the woman’s abdomen or using a small catheter inserted through the cervix by a doctor. The method used depends on the location of the baby and the placenta.
• Another diagnostic test called amniocentesis is performed from 15 weeks of pregnancy onward. A thin needle is inserted through the woman’s abdomen into the amniotic sac to withdraw a small sample of fluid from around the developing baby in amniocentesis.
Cloud-based stages have an extraordinary preferred position in permitting the clinician and their representatives to design cases distantly while travel and medical clinic access limitations are set up. With the careful plans and embeds chose early, embed providers and emergency clinics have the chance to enhance their stock and creation (on account of patient-explicit custom parts) to address the accumulation of cases once the circumstance permits effectively.

IMPACT ON SUPPLY
Because of the pertinacious COVID-19 lockdown, sanctions have been forced by administrations of different nations. These limitations and boundaries across the nation’s borders prompted a diminishing stockpile because of restricted materials and labor force, and the halting of assembly line.
The supply chain units are taking stringent measures and risk mitigation protocols to provide the devices to the manufacturers to the customer. The presence of key market players for the development and launch of the prenatal testing and new born screening systems will increase the net sales and show a surplus growth in the market.
Additionally, the manufacturers are also taking crucial steps to ensure the availability of raw materials by and also they have to look into the quality of products. But since the demand is increasing day by day, to meet the demand, the major manufacturers and suppliers collaborate to ensure the supply of raw materials.
IMPACT ON PRICE
Because of COVID-19, the market is upset to a major level. The few foundations need to stay shut while others to downsize the activities or put on pause extension plans as they attempted to endure the uncommon emergency.
Now, as the demand for telehealth innovation is turning out to be very demanding by human being, and this will make the market more competitive due to new and more innovative equipment that will be launched by the makers, by decreasing the overall cost of the new and innovative prenatal testing & newborn screening systems and solutions.
The current COVID-19 episode has influenced every industry on earth, and prenatal testing & newborn screening market is no exemption. There has been a tremendous and sudden lessening in the volume of elective joint substitutions worldwide as wellbeing situation legitimately organize their COVID-19 reaction.
States must develop and implement policies that allow for interstate licensure and practice of medicine (entailing the use of telemedicine) to enable consultation and communication to remote areas and ensure the swift flow of information across state lines.

CONCLUSION
All three components (blood spot screening, hearing, and CCHD screening) of newborn screening are requisite for babies and should still occur during the COVID-19 pandemic. Babies with newborn screening conditions still need to undergo monitoring and treatment promptly for newborn screening conditions during the COVID-19 pandemic. State and territory newborn screening programs are still conducting the newborn screening. Babies should still receive newborn screening during the COVID-19 pandemic.
Local manufacturers are now adapting new and better characteristics to create enormous supply measures to address the issue in coming fates and also the government is also helping to defeat all the difficulties faced in these unprecedented times. It is estimated that the COVID-19 pandemic outbreak has a negative impact on the growth of the global minimally invasive gastrointestinal surgical systems market.
The growing prevalence of genetic diseases has necessitated a stable healthcare network and adequate emergency medical services (EMS). However, certain challenges in Research and Development and the loss of patent of the devices may hamper the market growth.
The sales of prenatal testing and newborn screening tests services and related goods by entities (organizations, sole traders and partnerships) that offers prenatal testing and newborn screening tests, which aids in determining various genetic and chromosomal diseases, to furnish timely medical or surgical treatment of a condition before or after birth.
Moreover, the wider adoption of these systems is expected to increase to meet the rising demand for prenatal testing and newborn screening across the globe and overcome the shortage of healthcare professionals to perform such testing and screening. In the wake of the pandemic, current industry players with a substantial market share that consumed cash-rich and good management teams would prosper. Making the correct actions would enable businesses to demonstrate preparation and offer end-users reliability